JACKSONVILLE, Fla., Feb. 11 /PRNewswire-FirstCall/ -- Further to Phlo
Corporation's ("Phlo"") (OTC: PHLC) press release of December 27, 2007,
"Phlo Affiliate Begins Roll Out to Metropolitan New York City Account
Base," an affiliate of Phlo (the "Company") announced today that the
Company's distributor in Metropolitan New York City has sold and delivered
AQISS(TM) to the following initial retail accounts of its key account base
as part of such roll out. AQISS(TM) is currently available for sale to the
public in the retail accounts as follows:
-- New York Stock Exchange cafeteria
-- Morgan Stanley cafeteria
-- LA Sports Club
-- City Market
-- Crown Gourmet
-- Midtown Deli
-- Gold's Gym
-- Columbus Natural Food
-- Green Emporium
-- Hampton Deli
-- Central Market
-- Village Gourmet Deli
-- West Side Market
-- Elm Health
-- Karrot Health Food Store
-- Organic Market
The Company will announce further sales and shipments to new retail accounts as progress occurs.
In addition, the Company will conduct a free public sampling of AQISS(TM) at Morgan Stanley (1 New York Plaza, New York, New York -- Broad Street south of Water Street) at noon on Wednesday, February 13, 2008. Morgan Stanley has purchased AQISS(TM) for sale in its cafeteria. The Company will conduct sampling programs at a number of accounts that have purchased AQISS(TM) for sale to the public. The Company will announce the location and date of some of these samplings as they are scheduled.
AQISS(TM) features the Company's Instant Nano Hydration and Cell Armor technologies, providing instant, direct delivery of rehydration and cell-repair-and-protection payloads into the bloodstream beginning through the membranes of the mouth. These Instant Nano Hydration and Cell Armor technologies help provide sustained wellness necessary for life's performances and vigorous longevity. In addition, the Company's nano-encapsulation technology prevents the destruction of its active payloads in the stomach.
Phlo is a biotechnology company and a manufacturer and marketer of products (primarily liquids) containing patented and patent-pending biotechnologies. Phlo is focusing its technology generation and acquisition efforts on those technologies related to enhancing cognition and personal performance, reducing the effects of aging, and preventing or ameliorating cancer.
Certain statements made herein that are not historical constitute "forward-looking" statements within the meaning of the Private Litigation Reform Act of 1995 and may contain words such as "anticipate," "believe," "expect," "future," "may," "will," "should," "plan," "projected," "intend," and similar expressions to identify such forward-looking statements. Such statements are based on a number of assumptions and on information and estimates supplied to Phlo Corporation by sources currently available to it. Such assumptions and estimates are subject to uncertainties, contingencies, and other factors, many of which are beyond Phlo Corporation's control. Actual results may differ materially from the statements set forth above.
|SOURCE Phlo Corporation|
Copyright©2008 PR Newswire.
All rights reserved